THERAPEUTIC CLEARANCE OF COMPLEMENT C5A

拟议研究的总体目标是提供一个具体的、 成人高危人群C5a失活的实用方法 呼吸窘迫综合征(ARDS)。C5a是一个关键贡献者， 可能是ARDS病理过程中的必要因素。 文献中记录的能够灭活C5a的蛋白质 都有很差的特征。赛纳根的科学家们已经选择了一个 从人体组织中分离出这些蛋白质，然后鉴定 它的行动模式。基于这种生物活性的化验将 用于蛋白质的纯化、鉴定、克隆和表达 重组DNA技术。通过减少C5a在 有ARDS风险的患者，我们预计这种蛋白质将提供 一种有效的治疗药物，用于预防或改善 病理学。

The overall goal of the proposed research is to provide a specific, practical means for inactivating C5a in patients at risk of adult respiratory distress syndrome (ARDS). C5a is a key contributory, possibly necessary factor in the pathological course of ARDS. The proteins capable of inactivating C5a noted in the literature are poorly characterized. Synergen's scientists have selected one of these proteins to isolate from human tissue, then characterize its mode of action. An assay based on this biological activity will be used to purify, characterize, clone and express the protein by recombinant DNA technologies. By reducing the action of C5a in patients at risk for ARDS, we expect that the protein will provide a useful therapeutic agent for prevention or amelioration of the pathology.